Category: Pα+ - Page 3 - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics Field Remains Unclear; The Jurvetsons Discuss Psychedelics at DLD; GH Shares PoC Data

Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics Field Remains Unclear; The Jurvetsons Discuss Psychedelics at DLD; GH Shares PoC Data

Post published:January 24, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article mpathic Co-Founder Danielle Schlosser on AI Oversight of Psychedelics Trials

mpathic Co-Founder Danielle Schlosser on AI Oversight of Psychedelics Trials

Post published:January 17, 2025
Post category:Interviews Pα+

Read more about the article Patent Analysis: Lykos Suffers Blow from USPTO As All Patent Claims Stand Finally Rejected

Patent Analysis: Lykos Suffers Blow from USPTO As All Patent Claims Stand Finally Rejected

Post published:January 16, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to Cover IV Ketamine for Depression; Inside the Plan to Make Lykos MAPS Again

Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to Cover IV Ketamine for Depression; Inside the Plan to Make Lykos MAPS Again

Post published:January 11, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Post published:January 10, 2025
Post category:Analysis News Pα+

Read more about the article From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special Issue on Psychedelics

From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special Issue on Psychedelics

Post published:January 7, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #184: Federal Psychedelics Lobbying Jumps 90% in Q3’24, with MDMA-AT the Key Topic

Pα+ Psychedelic Bulletin #184: Federal Psychedelics Lobbying Jumps 90% in Q3’24, with MDMA-AT the Key Topic

Post published:December 31, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Post published:December 20, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #183: UW Madison’s Psychedelic Symposium; MindMed Doses First Phase 3 Patient; Beckley’s IV Psilocin Readout; Psilocybin for COVID Clinicians

Pα+ Psychedelic Bulletin #183: UW Madison’s Psychedelic Symposium; MindMed Doses First Phase 3 Patient; Beckley’s IV Psilocin Readout; Psilocybin for COVID Clinicians

Post published:December 18, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding

Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding

Post published:December 10, 2024
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.